Search results
Results From The WOW.Com Content Network
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today its key "Alnylam 5x15™" pipeline and partner program goals ...
US$1.04 billion (2022) [1] Number of employees. 2,100 (2023) [2] Website. alnylam .com. Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics [3] for genetically defined diseases. The company was founded in 2002 and is ...
June 24, 2024 at 4:08 AM. (Reuters) -Alnylam Pharmaceuticals said on Monday that its drug vutrisiran met the main goal in a late-stage study testing it as a treatment for a type of heart disease ...
News Home 06/25/2024 12:07 -0400 NEW HAVEN, Conn., June 25, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics , a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC) therapeutics, today announced that John Maraganore, Ph.D., has joined as a Strategic Advisor to the Company’s ...
The FDA panel voted 9 to 3 that the benefits of the drug, patisiran, outweigh its risks for treating patients with a type of heart muscle disease, cardiomyopathy, caused by a wild-type or ...
Analysts have said Alnylam's therapy needs to show a benefit in people whose high blood pressure is not controlled by existing drugs in order to differentiate itself in th Alnylam's gene-silencing ...
Alnylam Provides Key 2013 - 2014 Goals for RNAi Therapeutics Pipeline - Aims to Advance ALN-TTR02 into Phase III Pivotal Trial in Transthyretin (TTR)-Mediated Amyloidosis (ATTR) Patients with ...
Presented Pre-Clinical Data on Additional "Alnylam 5x15" Pipeline Programs. Also at ASH, Alnylam presented new pre-clinical data with ALN-TMP for the treatment of hemoglobinopathies.